Eggermont, Alexander MM; Kicinski, Michal; Blank, Christian U.; Mandala, Mario; Long, Georgina V.; Atkinson, Victoria; Dalle, Stéphane; Haydon, Andrew; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S.; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A.; Rutkowski, Piotr; Schadendorf, Dirk; Boers-Sonderen, Marye; Di Giacomo, Anna Maria; van den Eertwegh, Alfonsus JM; Grob, Jean Jacques; Gutzmer, Ralf; Jamal, Rahima; van Akkooi, Alexander C.J.; Lorigan, Paul; Grebennik, Dmitri; Kreplere, Clemens; Marreaud, Sandrine; Suciu, Stefan; Robert, Caroline
(Elsevier Limited, 2024-11)
In the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) than placebo ...